GlassScriptPhysician profile
Barry Weinreb
NPI 1720083710
$1,030.77
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $26.77 · 2021: $23.27 · 2022: $282 · 2023: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $266.22 | 2019-2022 | |
| Genzyme Corporation | $187.95 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $105.86 | 2023 | Tezspire, Breztri |
| Optinose US, INC. | $103.73 | 2019-2023 | |
| Kaleo, INC. | $81.14 | 2019-2023 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $73.18 | 2022-2023 | Dupixent |
| Alk-Abello, INC | $41.52 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $30.33 | 2023 | Orladeyo |
| Amgen INC. | $29.38 | 2023 | Tezspire |
| Aimmune Therapeutics, INC. | $27.64 | 2022 | |
| Incyte Corporation | $27.11 | 2022 | |
| Abbott Laboratories | $18.33 | 2022 | |
| Blueprint Medicines Corporation | $14.30 | 2023 | Ayvakit |
| Csl Behring | $12.04 | 2019 | |
| Merck Sharp & Dohme LLC | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Weinreb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.